A Pilot Placebo-Controlled Study of Trazodone and Buspirone in Alzheimers Disease
J.L. Hill
Bok Engelsk 1994
| Utgitt | BA Lawlor St James Hosp Old Age Psychiat Sect , 1994
|
|---|---|
| Omfang | 5 s.
|
| Opplysninger | Abstract The pharmacological management of behavioral symptoms in Alzheimer's disease is limited by the dearth of effective agents in this area. The purpose of this study was to determine whether trazodone or buspirone are helpfull in the treatment of behavioral disturbance in AD. Ten patients meeting NINCDS criteria for AD with behavioral complications were administered trazodone (up to 50 mg tid), buspirone (10mg tid), and placebo in a 12 week double-blind, crossover design. Outcome measures were the Brief Psychiatric Rating Scale (BPRS), the Dementia Mood Assessment Scale (DMAS), and the Buschke Selective Reminding Task. The data were analyzed by ANOVA. Compared to placebo, trazodone produced a small but significant reduction in BPRS and DMAS scores (p<0.05), indicating improvement in behavior but no change in cognitive measures. In contrast, buspirone has no significant effect on either behavioral or cognitive measures compared to placebo. The results of this pilot study suggest a beneficial role for trazodone, but not buspirone, in the treatment og behavioral disturbance in AD. Further studies using a wider range of doses of trazodone in more behaviorally disturbed AD patients should now be initiated in an attempt to replicate and expand on this preliminary fidings.
|
| Emner | |
| ISSN |
